TY - JOUR
T1 - LDL-Cholesterol Is Not the Only Clinically Relevant Biomarker for Coronary Artery Disease or Acute Coronary Syndrome
AU - Field, Patrick A.
AU - Vasan, Ramachandran S.
N1 - Publisher Copyright:
© 2018 American Society for Clinical Pharmacology and Therapeutics
PY - 2018/8
Y1 - 2018/8
N2 - Coronary artery disease (CAD) is a progressive disorder and its risk is best determined using multiple biomarkers and risk factors. Many novel biomarkers have been shown to improve cardiovascular disease risk beyond that of the traditional risk factors, including polygenic risk scores, small very low-density lipoprotein (VLDL), ApoB, triglycerides (TG), non-HDL-c, lipoprotein (a) (Lp(a)), coronary calcium scores, C-reactive protein (CRP), B-type natriuretic peptide (BNP), troponins, and many other novel biomarkers that have been measured using high throughput assays.
AB - Coronary artery disease (CAD) is a progressive disorder and its risk is best determined using multiple biomarkers and risk factors. Many novel biomarkers have been shown to improve cardiovascular disease risk beyond that of the traditional risk factors, including polygenic risk scores, small very low-density lipoprotein (VLDL), ApoB, triglycerides (TG), non-HDL-c, lipoprotein (a) (Lp(a)), coronary calcium scores, C-reactive protein (CRP), B-type natriuretic peptide (BNP), troponins, and many other novel biomarkers that have been measured using high throughput assays.
UR - http://www.scopus.com/inward/record.url?scp=85050452829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050452829&partnerID=8YFLogxK
U2 - 10.1002/cpt.1126
DO - 10.1002/cpt.1126
M3 - Article
C2 - 30004115
AN - SCOPUS:85050452829
SN - 0009-9236
VL - 104
SP - 232
EP - 234
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 2
ER -